TLC 388
| Code | Size | Price |
|---|
| TAR-T28982-5mg | 5mg | £850.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
TLC 388, a DNA topoisomerase I inhibitor, is used potentially for the treatment of Renal carcinoma and Hepatocellular carcinoma
CAS:
1432468-79-5
Formula:
C39H30N8O15
Molecular Weight:
850.71
Purity:
0.98
SMILES:
CC[C@@]1(OC(=O)C(C)ON=C2c3cc(cc(c3-c3c2cc(cc3[N+]([O-])=O)[N+]([O-])=O)[N+]([O-])=O)[N+]([O-])=O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O
References
1. Ghamande S, Lin CC, Cho DC, Shapiro GI, Kwak EL, Silverman MH, Tseng Y, Kuo MW, Mach WB, Hsu SC, Coleman T, Yang JC, Cheng AL, Ghalib MH, Chuadhary I, Goel S. A phase 1 open-label, sequential dose-escalation study investigating the safety, tolerability, and pharmacokinetics of intravenous TLC388 administered to patients with advanced solid tumors. Invest New Drugs. 2014 Jun;32(3):445-51. doi: 10.1007/s10637-013-0044-7. PubMed PMID: 24271274.
2. Huang G, Wang H, Yang LX. Enhancement of radiation-induced DNA damage and inhibition of its repair by a novel camptothecin analog. Anticancer Res. 2010 Mar;30(3):937-44. PubMed PMID: 20393017.